Research Themes

Health economics of melanoma and kidney disease


PhD, MScMed(Clin Epi)(Hons)

Prof Rachael Morton

Acting Deputy Director

Professor Rachael Morton is Acting Deputy Director at CTC and also leads the Health Economics and Health Technology Assessment teams. Rachael specialises in trial-based and modelled economic evaluation, and elicitation of patient preferences using discrete choice experiments. Her research incorporates patient-centred and economic outcomes into clinical trials of diagnostic tests, new treatments and models of care to facilitate policy decision-making on the basis of cost-effectiveness.

Research interests

  • Health economics of melanoma
  • Chronic kidney disease.
  • Health equity in disadvantaged populations both in Australia and overseas.
  • Systematic reviews of economic evidence
  • Assessment of test evaluation and monitoring
  • Measurement of quality of life and well-being
  • End-of-life care

Teaching and supervision

Rachael is coordinator for one unit of study in health economics within the Masters programmes in the Sydney Medical School / School of Public Health: Health Economics in Trials (CLTR 5006). She coordinates short courses in health economics for government and industry and currently supervises five PhD candidates.


  • Within-trial and modelled economic evaluation
  • Preference elicitation
  • Outcomes assessment
  • Health equity
  • Chronic Kidney Disease
  • Melanoma and other cancers

Professional Associations

  • President, Health Services Research Association of Australia and New Zealand (HSRAANZ), member since 2011
  • Australian Clinical Trials Alliance (ACTA) member since 2016; Co-chair ACTA Reference Group – “Research Prioritisation: tools and criteria” since 2017
  • Health Economists’s Clinical Trials Alliance (HECTA) – Founding member since 2016
  • International Society for Pharmacoeconomic and Outcomes Research (ISPOR), member since 2009
  • International Health Economics Association (IHEA) Program Chair 2018/19, member since 2008
  • Health Economists Study Group – UK (HESG) member since 2010
  • Cochrane Equity Methods Group member since 2013
  • Australia and New Zealand Society of Nephrology (ANZSN) member since 1996
  • Australia and New Zealand Melanoma Trials Group (ANZMTG) Founding member since 2003
  • Expert Reference Group member, Renal node - Joanna Briggs Institute member since 2012


View Rachael's publications.